ImmunoGen falls after modifying ovarian cancer trial

ImmunoGen Inc. (NASDAQ:IMGN) sank $1.60 (19%) to $6.85 on Friday after disclosing it is modifying the FORWARD I trial of its lead internal program, mirvetuximab soravtansine ( IMGN853). The company changed the study's

Read the full 335 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE